Dr Shawn Manning is a adviser to the life science industry, specialising in corporate strategy, asset optimisation and and delivery of shareholder value. He has over 25 years of international Life Sciences experience, including over 12 years as a rated equity analyst (with Dresdner Kleinwort Benson, SG-Cowen/ Societe Generale, Bridgewell / Landsbanki and Singer Capital Markets), covering ‘Big Pharma’, speciality/emerging pharmaceutical, medical technology and biotechnology stocks. In this role he has advised institutional, VC and PE investors, and provided strategic support and advice to management teams, supporting the raising of over £700m in new funding for Life Science companies.
Manning previously consulted to the pharmaceutical industry, and managed the Healthcare practice for Datamonitor. In this capacity he worked alongside major European, US and Japanese pharmaceutical companies, leading consultancy projects focusing on strategic product positioning, including portfolio, opportunity and pricing analysis. Manning originally specialised in infectious disease, and holds a Doctorate from the University of Oxford (Hertford College), and an undergraduate degree from Imperial College, London.
He is a Visiting Lecturer to the Masters in Bioscience Enterprise (MBE) course at the University of Cambridge, a Fellow of the Royal Society of Medicine (FRSM), a member of the OBN Advisory Board, and Chairman of OBN’s investment and Tax Special Interest Group (ITSIG).
Manning is Managing Director and Founder of Akesios Associates, a specialist advisory firm providing financial strategy, representation and commercial development advice to Life Science companies, with a current focus on company strategy, asset optimisation and shareholder value. He is also a Senior Adviser for Outcome Capital, a Boston-based investment bank specialising in Life Science M&A.